Plain-English translation of NCT06976268 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Parkinson Disease research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This research study is testing a new medication called to see if it can help people who have been recently diagnosed with Parkinson's disease. Researchers want to find out if the medication works, is safe to take, and doesn't cause troubling side effects. About 550 people will participate, with some receiving the medication at different doses and others receiving a placebo (a pill with no active ingredient).
Currently, there are treatments for Parkinson's disease, but researchers are looking for new options that might help people early in their diagnosis. This trial is designed to test whether this medication could offer a new way to slow symptoms or improve quality of life for people newly diagnosed with Parkinson's.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will be randomly assigned to take either the new medication at one of two doses or a placebo pill. You won't know which group you're in — that's what 'double-blind' means. You'll visit the research clinic regularly so doctors can check how you're doing, watch for any side effects, and measure whether your symptoms are changing. The study involves both Phase 2 and Phase 3 research, which means it's testing the medication's safety and effectiveness in a careful, step-by-step way.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
United States